Current studentsExisting staffContact us
 

Synergistic role of self-emulsifying lipids and nanostructured porous silica particles in optimizing the oral delivery of lovastatin

Simple item page
dc.contributor.authorRao, S.
dc.contributor.authorTan, A.
dc.contributor.authorBoyd, B.J.
dc.contributor.authorPrestidge, C.A.
dc.date.issued2014
dc.description.abstractAim: To investigate the role of self-emulsifying lipids and porous silica particlesin enhancing supersaturated drug loading and biopharmaceutical performanceof nanostructured silica-lipid hybrid (SLH) systems. Conclusion: In conclusion, SLHs profit from advantages associated with both self-emulsifying lipids and porous silica, and provide potentially improved therapyagainst coronary artery disease. Materials & methods: Two lovastatin (LOV)-SLHs were engineered from self-emulsifying lipid (Gelucire® 44/14; Gattefossé, Lyon, France) and Aerosil® 380 (SLH-A; Evonik Industries, Essen, Germany) or Syloid® 244FP silica (SLH-S; Grace Davison Discovery Sciences, Rowville, Australia). Results & discussion: The LOV-SLHs encapsulated LOV at 10% w/w, which is ≥3-foldhigher than typical lipid formulations in the absence of porous silica. The LOV-SLHsretained self-emulsifying lipid-associated solubilization benefits and improved drug solubilization by twofold in simulated intestinal condition. SLH-S, with larger surface area (299 m2/g), was superior to SLH-A (184 m2/g) in optimizing oral bioavailability, suggesting a critical role of the silica geometry. Bioavailability of SLH-S was 2.8- and1.3-fold higher than pure drug and drug suspension in Gelucire 44/14, respectively.
dc.identifier.citationNanomedicine, 2014; 9(18):2745-2759
dc.identifier.doi10.2217/NNM.14.37
dc.identifier.issn1743-5889
dc.identifier.issn1748-6963
dc.identifier.urihttps://hdl.handle.net/1959.8/159862
dc.language.isoen
dc.publisherFuture Medicine Ltd
dc.relation.fundingARC
dc.relation.fundingAustralian Biotech Ceridia Pty Ltd
dc.relation.fundingAustralian National Health and Medical Research Council
dc.relation.fundingBioinnovation South Australia
dc.relation.fundingITEK Pty Ltd
dc.rightsCopyright 2014 Future Medicine
dc.source.urihttps://doi.org/10.2217/NNM.14.37
dc.subjectbioavailability
dc.subjectovastatin
dc.subjectoral delivery
dc.subjectporous silica particle
dc.subjectself-emulsifying lipid
dc.subjectsilica-lipid hybrid
dc.titleSynergistic role of self-emulsifying lipids and nanostructured porous silica particles in optimizing the oral delivery of lovastatin
dc.typeJournal article
pubs.publication-statusPublished
ror.mmsid9915914023901831

Files

Collections